Antares Pharma, Inc. (NASDAQ: ATRS) today announced that the last
patient has been enrolled in a double-blind, multiple-dose, phase 3
study to evaluate the efficacy and safety of QuickShot ®
Testosterone (QS T) administered subcutaneously once each week to
testosterone-deficient adult males.
Antares Pharma, Inc. (NASDAQ: ATRS) today announced it will release its
third quarter 2014 financial results before the market opens on
Thursday, November 6, 2014 and host a conference call at 8:30 a.m. ET
(Eastern Time) to discuss the results.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.